Clonogenic assay demonstrates dose-dependent effects of MEK inhibitor AZD6244 and MCL-1 inhibitor S63845 on triple-negative breast cancer, indicating potential therapeutic strategies.
Fig. S4 Effect of combination of drugs on SUM149-R cells. The clonogenic assay shows a significant dose-dependent decrease in the colony formation capability of SUM149-R cells after treatment with the combination of MEKK inhibitor AZD6244 and MCL-1 inhibitor S63845 at the same time.
No takes yet. Share an insight, caveat, or question.
Mughees et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: